Citation Impact
Citing Papers
2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease
2010 Standout
Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation
2009 Standout
Risk Factors for Venous Thromboembolism
2003 Standout
Epidemiological characteristics of platelet aggregability.
1985
Effect of heart rate control on coagulation status in patients of rheumatic mitral stenosis with atrial fibrillation – A pilot study
2015
Clotting state after cardioversion of atrial fibrillation: a haemostasis index could detect the relationship with the arrhythmia duration.
2005
Association between mortality and indicators of traffic-related air pollution in the Netherlands: a cohort study
2002 Standout
Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function
2001
Short-Term Effects of Nose-Only Cigarette Smoke Exposure on Glutathione Redox Homeostasis, Cytochrome P450 1A1/2 and Respiratory Enzyme Activities in Mice Tissues
2013 Standout
Mechanisms of Thrombus Formation
2008 Standout
Peripheral Arterial Disease Detection, Awareness, and Treatment in Primary Care
2001 Standout
Diabetic retinopathy
2010 Standout
Multiple Biomarkers for the Prediction of First Major Cardiovascular Events and Death
2006 Standout
Platelet adhesion in atrial fibrillation
2007
Particulate air pollution and acute health effects
1995 Standout
D-dimer: a characteristic of the coagulation state of each patient with chronic atrial fibrillation
2002
Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans
1990
Pulmonary and Systemic Oxidant/Antioxidant Imbalance in Chronic Obstructive Pulmonary Disease
2005
Chronic Venous Disease
2006 Standout
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
2002 Standout
Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16‐year period
1997
Mechanisms linking obesity with cardiovascular disease
2006 StandoutNature
Hypofibrinolysis in atrial fibrillation
1998
Is there a hypercoagulable phase during initiation of antithrombotic therapy with oral anticoagulants in patients with atrial fibrillation?
2003
Correlation between left atrial size, prothrombotic state and markers of endothelial dysfunction in patients with lone chronic nonrheumatic atrial fibrillation
2000
Exercise Standards for Testing and Training
2013 Standout
Anticoagulant Therapy Modifies Fibrinolytic Dysfunction in Chronic Atrial Fibrillation
2000
Paroxysmal atrial fibrillation
2001
Aspirin plus Clopidogrel as Secondary Prevention after Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis
2014 Standout
C-reactive protein: a critical update
2003 Standout
Accumulation of risk factors enhances the prothrombotic state in atrial fibrillation
2007
Pathophysiologic Correlates of Thromboembolism in Nonvalvular Atrial Fibrillation: II. Dense Spontaneous Echocardiographic Contrast (The Stroke Prevention in Atrial Fibrillation [SPAF-III] Study)
1999
Antithrombotic Therapy in Peripheral Arterial Occlusive Disease
1998
Does atrial fibrillation confer a hypercoagulable state?
1995
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
2013 Standout
von Willebrand factor and coronary heart disease. Prospective study and meta-analysis
2002
Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation
2004
Whole blood coagulation on protein adsorption-resistant PEG and peptide functionalised PEG-coated titanium surfaces
2004 StandoutNobel
Clinical Implications of Prostaglandin and Thromboxane A2Formation
1988
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
2009 Standout
Association of Fibrinogen, C-reactive Protein, Albumin, or Leukocyte Count With Coronary Heart Disease
1998 Standout
Abnormal membrane concentrations of 20 and 22-carbon essential fatty acids: A common link between risk factors and coronary and peripheral vascular disease?
1995
Haemostatic Activity in Patients with Atrial Fibrillation Treated with Low-Molecular-Weight Heparin Before and After Electrical Cardioversion
2004
Plasma adenosine levels and platelet activation in patients with atrial fibrillation
1999
Coagulation indicators in patients with paroxysmal atrial fibrillation: Effects of electric and pharmacologic cardioversion
2000
Prediction of left atrial appendage thrombi in non-valvular atrial fibrillation
2007
Lifestyle factors and the risk of varicose veins Edinburgh Vein Study
2003
Obesity, haemostasis and the fibrinolytic system
2002
Diabetes and Atherosclerosis
2002 Standout
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
2009 Standout
Air pollution and health
2002 Standout
C-Reactive Protein and Other Circulating Markers of Inflammation in the Prediction of Coronary Heart Disease
2004 Standout
Oxidative stress and regulation of glutathione in lung inflammation
2000
Elevated C-Reactive Protein Levels in Overweight and Obese Adults
1999 Standout
Clinical Implications of Prostaglandin and Thromboxane A2Formation
1988
Regulatory Functions of the Vascular Endothelium
1990 StandoutNobel
Prediction of Proliferative Diabetic Retinopathy With Hemoglobin Level
2009
Diabetes mellitus
2001
Activation of coagulation occurs after electrical cardioversion in patients with chronic atrial fibrillation despite optimal anticoagulation with warfarin
2004
Mejoría de la función fibrinolítica tras el tratamiento anticoagulante en la fibrilación auricular reumática crónica
1999
A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation
2002
Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage
2001
Atrial Fibrillation and the Hypercoagulable State: From Basic Science to Clinical Practice
2003
Effects of blood pressure on the prothrombotic risk in 1235 patients with non-valvular atrial fibrillation
2006
D-dimer level influences thromboembolic events in patients with atrial fibrillation
2005
Role of oxidants/antioxidants in smoking-induced lung diseases
1996
Global burden of COPD: risk factors, prevalence, and future trends
2007 Standout
Angiogenic factors in atrial fibrillation: A possible role in thrombogenesis?
2005
Intravenous Ancrod for Treatment of Acute Ischemic Stroke
2000
Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited
2009 Standout
Dabigatran With or Without Concomitant Aspirin Compared With Warfarin Alone in Patients With Nonvalvular Atrial Fibrillation (PETRO Study)
2007
Von Willebrand factor, fibrinogen, and soluble P-selectin levels after mitral valve replacement versus mitral valve repair
2000
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
2001 Standout
Oxidative Stress in Chronic Obstructive Pulmonary Disease
1997 Standout
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
2012 Standout
Guidelines for the Early Management of Patients With Acute Ischemic Stroke
2013 Standout
Markers of Inflammation and Cardiovascular Disease
2003 Standout
Thrombogenesis in Mitral Regurgitation and Aortic Stenosis
1996
Natural Product Synthesis Using Multicomponent Reaction Strategies
2009 Standout
ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic)
2006 Standout
Air Pollution and Cardiovascular Disease
2004 Standout
C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis
2009 Standout
Physical Activity and Hemostatic and Inflammatory Variables in Elderly Men
2002
Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.
1994 Standout
Relationship of interleukin-6 and C-Reactive protein to the prothrombotic state in chronic atrial fibrillation
2004
Adventures and Excursions in Bioassay: The Stepping Stones to Prostacyclin (Noble Lecture)
1983 Nobel
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons
2019 Standout
Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation.
1997
Putative mechanism of hypotensive action of platelet-activating factor in dogs.
1992 StandoutNobel
Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ
1997 Standout
Thrombotic Variables and Risk of Idiopathic Venous Thromboembolism in Women Aged 45-64 Years
2000
Effects of Fixed Low-Dose Warfarin, Aspirin-Warfarin Combination Therapy, and Dose-Adjusted Warfarin on Thrombogenesis in Chronic Atrial Fibrillation
2000
Plasma von Willebrand Factor and Soluble P-Selectin as Indices of Endothelial Damage and Platelet Activation in 1321 Patients With Nonvalvular Atrial Fibrillation
2002
Prognostic Value of Plasma von Willebrand Factor and Soluble P-Selectin as Indices of Endothelial Damage and Platelet Activation in 994 Patients With Nonvalvular Atrial Fibrillation
2003
Additive Role of Plasma von Willebrand Factor Levels to Clinical Factors for Risk Stratification of Patients With Atrial Fibrillation
2006
Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban
2016
HAEMOSTATIC FUNCTION AND ISCHAEMIC HEART DISEASE: PRINCIPAL RESULTS OF THE NORTHWICK PARK HEART STUDY
1986 Standout
The Hypercoagulable States
1985
Effects of Anticoagulation Intensity on Hemostatic Markers in Patients With Non-Valvular Atrial Fibrillation
2003
Reply: Fibrin D-dimer levels and thromboembolic events in patients with atrial fibrillation
2006
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2020 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Antithrombotic Therapy in Peripheral Arterial Occlusive Disease
1992
Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure
2007 StandoutNobel
Large-Scale Applications of Transition Metal-Catalyzed Couplings for the Synthesis of Pharmaceuticals
2011 Standout
Plasma Concentration of Interleukin-6 and the Risk of Future Myocardial Infarction Among Apparently Healthy Men
2000 Standout
Markers of Thrombin and Platelet Activity in Patients With Atrial Fibrillation
1999
Synergistic effect of HIF-1α gene therapy and HIF-1-activated bone marrow-derived angiogenic cells in a mouse model of limb ischemia
2009 StandoutNobel
Passage of Inhaled Particles Into the Blood Circulation in Humans
2002 Standout
Effect of prostacyclin on vascular capacity in the dog.
1985
Increased Expression of P-Selectin on Platelets Is a Risk Factor for Silent Cerebral Infarction in Patients With Atrial Fibrillation
1998
Mediators produced by the endothelial cell.
1988 Nobel
Is Thrombogenesis in Atrial Fibrillation Related to Matrix Metalloproteinase-1 and Its Inhibitor, TIMP-1?
2003
Atrial Fibrillation and the Prothrombotic State in the Elderly
2003
The Intramolecular Asymmetric Pauson−Khand Cyclization as a Novel and General Stereoselective Route to Benzindene Prostacyclins: Synthesis of UT-15 (Treprostinil)
2004
Fibrin D-Dimer and Coronary Heart Disease
2001
Fibrin d -Dimer and β-Thromboglobulin as Markers of Thrombogenesis and Platelet Activation in Atrial Fibrillation
1996
Works of G.D.O. Lowe being referenced
Blood rheology and outcome in the West of Scotland Coronary Prevention Study
1997
Relationship between plasma essential fatty acids and smoking, serum lipids, blood pressure and haemostatic and rheological factors
1994
Haemostatic factors and risk of varicose veins and chronic venous insufficiency: Edinburgh Vein Study
2000
Changes in Neutrophil Deformability following In Vitro Smoke Exposure: Mechanism and Protection
1992
Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment.
1995
Contribution of the Haematocrit to the Bleeding Time
1983
Effect of Warfarin and Aspirin Therapy on Plasma Fibrinogen and Fibrin d -Dimer levels in Patients with chronic Atrial Fibrillation
1993
Effect of Insulin Therapy on Coagulation and Platelet Function in Type II (Non-Insulin-Dependent) Diabetes mellitus
1986
Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study
1999
Subcutaneous Ancrod after Operation for Fractured Hip - a Dose-Ranging and Feasibility Study
1978
EPOPROSTENOL (PROSTACYCLIN) AND SEVERE ARTERIAL DISEASE
1983
Fibrin D-dimer, von Willebrand factor and tissue plasminogen activator inhibitor antigens are predictive of major ischaemic heart disease
1995
Laboratory Evaluation of Hypercoagulability
1981
Abnormal blood viscosity and haemostasis in long-standing retinal vein occlusion.
1983
Epidemiology of haematocrit, white cell count, red cell aggregation and fibrinogen: The Glasgow MONICA study
1992